<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">mimmun</journal-id><journal-title-group><journal-title xml:lang="ru">Медицинская иммунология</journal-title><trans-title-group xml:lang="en"><trans-title>Medical Immunology (Russia)</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1563-0625</issn><issn pub-type="epub">2313-741X</issn><publisher><publisher-name>SPb RAACI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.15789/1563-0625-IOT-2770</article-id><article-id custom-type="elpub" pub-id-type="custom">mimmun-2770</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>КРАТКИЕ СООБЩЕНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>SHORT COMMUNICATIONS</subject></subj-group></article-categories><title-group><article-title>Идентификация Th1-поляризованных клеток Th17: решение проблемы</article-title><trans-title-group xml:lang="en"><trans-title>Identification of Th1-polarized Th17 cells: solving the problem</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2173-2724</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Куклина</surname><given-names>Е. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Kuklina</surname><given-names>E. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Куклина Е.М. – д.б.н., ведущий научный сотрудник лаборатории иммунорегуляции </p><p>614081, г. Пермь, ул. Голева, 13.</p></bio><bio xml:lang="en"><p>Kuklina E.M., PhD, MD (Biology), Leading Research Associate, Laboratory of Immunoregulation </p><p>13 Golev St, Perm, 614081</p></bio><email xlink:type="simple">ibis_07@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9891-0509</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Глебездина</surname><given-names>Н. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Glebezdina</surname><given-names>N. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Глебездина Н.С. – к.б.н., младший научный сотрудник лаборатории иммунорегуляции </p><p>614081, г. Пермь, ул. Голева, 13.</p></bio><bio xml:lang="en"><p>Glebezdina N.S., PhD (Biology), Junior Research Associate, Laboratory of Immunoregulation </p><p>13 Golev St, Perm, 614081</p></bio><email xlink:type="simple">glebezdina_n@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Институт экологии и генетики микроорганизмов Уральского отделения Российской академии наук – филиал ФГБУН «Пермский федеральный исследовательский центр Уральского отделения Российской академии наук»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Institute of Ecology and Genetics of Microorganisms, Perm Federal Research Center, Ural Branch, Russian Academy of Sciences</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2023</year></pub-date><pub-date pub-type="epub"><day>01</day><month>06</month><year>2023</year></pub-date><volume>25</volume><issue>4</issue><fpage>731</fpage><lpage>734</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Куклина Е.М., Глебездина Н.С., 2023</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="ru">Куклина Е.М., Глебездина Н.С.</copyright-holder><copyright-holder xml:lang="en">Kuklina E.M., Glebezdina N.S.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.mimmun.ru/mimmun/article/view/2770">https://www.mimmun.ru/mimmun/article/view/2770</self-uri><abstract><p>Т-хелперы, продуцирующие IL-17 (Th17), обладают высокой пластичностью: рестимуляция лимфоцитов в воспалительном окружении способна индуцировать их трансформацию в клетки с другим фенотипом, и наиболее частым является сдвиг в направлении Th1. Результатом такой трансформации является появление клеток, экспрессирующих наряду с классическими маркерами клеток Th17 ключевые Th1-ассоциированные молекулы. В наиболее общей форме такая популяция представлена CD4+CD161+CCR6+CXCR3+IL-17+IFNγ+Т-клетками, и в современной литературе она чаще всего обозначается как Th17.1. Часть клеток Th17.1 может полностью утрачивать продукцию IL-17, сохраняя при этом экспрессию других Th17-ассоциированных молекул, – это так называемые клетки ex-Th17 (CD4+CD161+CCR6+CXCR3+IL-17- IFNγ+Т-клетки). Как следствие, популяция Th1- поляризованных Th17 включает клетки Th17.1, ex-Th17 и ряд дополнительных переходных форм. Она имеет уникальные функциональные свойства – повышенный провоспалительный потенциал и способность преодолевать гистогематические барьеры. Именно этим клеткам в настоящее время отводится ключевая роль в патогенезе многих аутоиммунных заболеваний, а процесс редифференцировки Th17 в Th1 рассматривается как перспективная терапевтическая мишень. Однако развитие этого направления осложняет слабая сопоставимость данных о размерах такой популяции. Проведенный в рамках настоящей работы анализ методов определения Th1-поляризованных Th17 in vivo и in vitro позволил разрешить эти противоречия и разработать оптимальные подходы к идентификации данной популяции. В большинстве работ, особенно клинических, ее идентифицируют по коэкспрессии ключевых цитокинов (IL-17/IFNγ) или хемокиновых рецепторов (CCR6/CXCR3), редко – по их комбинации. При таком подходе коэкспрессия CCR6/CXCR3 маркирует общую популяцию Th1-подобных Th17, включающую и Th17.1, и ex-Th17, тогда как коэкспрессия цитокинов IL-17/IFNγ идентифицирует клетки Th17.1, а субпопуляцию ex-Th17 в этом случае ошибочно классифицируют как классические Th1. Такая «недооценка» субпопуляции ex-Th17 существенно занижает результаты, поскольку именно на долю ex-Th17 приходится основная часть Th1-подобных Th17. И только одновременная оценка коэкспрессии цитокинов и Th17-ассоциированных мембранных молекул позволяет идентифицировать клетки Th17.1 и ex-Th17 отдельно, что важно учитывать при интерпретации данных по проблеме и при планировании клинических исследований.</p></abstract><trans-abstract xml:lang="en"><p>Helper T cells producing IL-17 (Th17) have high plasticity: restimulation of lymphocytes in an inflammatory environment can induce their transformation into cells with another phenotype, and a shift towards Th1 is the most common. The result of this transformation is the appearance of cells expressing along with the classical markers of Th17 cells key Th1-associated molecules. In its most general form, this population is represented by CD4+CD161+CCR6+CXCR3+IL-17+IFNγ+Т cells, and in the current literature it is most often referred to as Th17.1. Some Th17.1 cells can completely lose the production of IL-17, while maintaining the expression of other Th17-associated molecules; these are the so-called ex-Th17 cells (CD4+CD161+CCR6+CXCR3+IL-17- IFNγ+Т cells). Consequently, the population of Th1-polarized Th17 includes Th17.1, ex-Th17 cells and a number of additional transitional forms. It has unique functional properties – an increased pro-inflammatory potential and the ability to overcome histohematic barriers. It is these cells that are currently assigned a key role in the pathogenesis of many autoimmune diseases, and the process of Th17 redifferentiation into Th1 is considered as a promising therapeutic target. However, the development of this direction is complicated by the weak comparability of data on the size of such a population. The analysis of methods for determining Th1-polarized Th17 in vivo and in vitro, carried out in this work, made it possible to resolve these contradictions and develop optimal approaches to identifying this population. In most studies, especially clinical ones, it is identified by co-expression of key cytokines (IL-17/IFNγ) or chemokine receptors (CCR6/CXCR3), rarely by their combination. In this approach, co-expression of CCR6/ CXCR3 marks the total population of Th1-like Th17, including both Th17.1 and ex-Th17, while co-expression of IL-17/IFNγ cytokines identifies only Th17.1 cells, and the subpopulation of ex-Th17 is misclassified as classic Th1 in this case. Such “underestimation” of the ex-Th17 subpopulation significantly marks down the results, since it is ex-Th17 that accounts for the bulk of Th1-like Th17. And only a simultaneous assessment of the co-expression of cytokines and Th17-associated membrane molecules allows identification Th17.1 and exTh17 cells separately, which is important to consider when interpreting data on the problem and when planning clinical trials.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>Th17</kwd><kwd>редифференцировка</kwd><kwd>Th1-поляризованные Th17</kwd><kwd>IFNγ-продуцирующие Th17</kwd><kwd>Th17.1</kwd><kwd>ex-Th17</kwd></kwd-group><kwd-group xml:lang="en"><kwd>Th17</kwd><kwd>redifferentiation</kwd><kwd>Th1-polarized Th17</kwd><kwd>IFNγ-producing Th17</kwd><kwd>Th17.1</kwd><kwd>ex-Th17</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Исследование выполнено при финансовой поддержке РНФ и Пермского края в рамках научного проекта № 22-25-20121</funding-statement><funding-statement xml:lang="en">The study was carried out with the financial support of the Russian Science Foundation and the Perm Territory within the framework of scientific project No. 22-25-20121.</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Annunziato F., Cosmi L., Santarlasci V., Maggi L., Liotta F., Mazzinghi B., Parente E., Fili L., Ferri S., Frosali F., Giudici F., Romagnani P., Parronchi P., Tonelli F., Maggi E., Romagnani S. Phenotypic and functional features of human Th17 cells. J. Exp. Med. 2007, Vol. 204, no. 8, pp. 1849-1861.</mixed-citation><mixed-citation xml:lang="en">Annunziato F., Cosmi L., Santarlasci V., Maggi L., Liotta F., Mazzinghi B., Parente E., Fili L., Ferri S., Frosali F., Giudici F., Romagnani P., Parronchi P., Tonelli F., Maggi E., Romagnani S. Phenotypic and functional features of human Th17 cells. J. Exp. Med. 2007, Vol. 204, no. 8, pp. 1849-1861.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Dankers W., den Braanker H., Paulissen S.M.J., van Hamburg J.P., Davelaar N., Colin E.M., Lubberts E. The heterogeneous human memory CCR6+ T helper-17 populations differ in T-bet and cytokine expression but all activate synovial fibroblasts in an IFNγ-independent manner. Arthritis Res. Ther., 2021, Vol. 23, no. 1, pp. 157. doi: 10.1186/s13075-021-02532-9.</mixed-citation><mixed-citation xml:lang="en">Dankers W., den Braanker H., Paulissen S.M.J., van Hamburg J.P., Davelaar N., Colin E.M., Lubberts E. The heterogeneous human memory CCR6+ T helper-17 populations differ in T-bet and cytokine expression but all activate synovial fibroblasts in an IFNγ-independent manner. Arthritis Res. Ther., 2021, Vol. 23, no. 1, pp. 157. doi: 10.1186/s13075-021-02532-9.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Dhaeze T., Tremblay L., Lachance C., Peelen E., Zandee S., Grasmuck C., Bourbonniere L., Larouche S., Ayrignac X., Rebillard R.M., Poirier J., Lahav B., Duquette P., Girard M., Moumdjian R., Bouthillier A., Larochelle C., Prat A. CD70 defines a subset of proinflammatory and CNS-pathogenic TH1/TH17 lymphocytes and is overexpressed in multiple sclerosis. Cell. Mol. Immunol., 2019, Vol. 16, no. 7, pp. 652-665.</mixed-citation><mixed-citation xml:lang="en">Dhaeze T., Tremblay L., Lachance C., Peelen E., Zandee S., Grasmuck C., Bourbonniere L., Larouche S., Ayrignac X., Rebillard R.M., Poirier J., Lahav B., Duquette P., Girard M., Moumdjian R., Bouthillier A., Larochelle C., Prat A. CD70 defines a subset of proinflammatory and CNS-pathogenic TH1/TH17 lymphocytes and is overexpressed in multiple sclerosis. Cell. Mol. Immunol., 2019, Vol. 16, no. 7, pp. 652-665.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Dhodapkar К.М., Barbuto S., Matthews P., Kukreja A., Mazumder A., Vesole D., Jagannath S., Dhodapkar M.V. Dendritic cells mediate the induction of polyfunctional human IL17-producing cells (Th17-1 cells) enriched in the bone marrow of patients with myeloma. Blood, 2008, Vol. 112, no. 7, pp. 2878-2885.</mixed-citation><mixed-citation xml:lang="en">Dhodapkar К.М., Barbuto S., Matthews P., Kukreja A., Mazumder A., Vesole D., Jagannath S., Dhodapkar M.V. Dendritic cells mediate the induction of polyfunctional human IL17-producing cells (Th17-1 cells) enriched in the bone marrow of patients with myeloma. Blood, 2008, Vol. 112, no. 7, pp. 2878-2885.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Duhen T., Campbell D.J. IL-1β promotes the differentiation of polyfunctional human CCR6+CXCR3+ Th1/17 cells that are specific for pathogenic and commensal microbes. J. Immunol., 2014, Vol. 193, no. 1, pp. 120-129.</mixed-citation><mixed-citation xml:lang="en">Duhen T., Campbell D.J. IL-1β promotes the differentiation of polyfunctional human CCR6+CXCR3+ Th1/17 cells that are specific for pathogenic and commensal microbes. J. Immunol., 2014, Vol. 193, no. 1, pp. 120-129.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Kebir H., Ifergan I., Alvarez J.I., Bernard M., Poirier J., Arbour N., Duquette P., Prat A. Preferential recruitment of interferon-gamma-expressing TH17 cells in multiple sclerosis. Ann. Neurol., 2009, Vol. 66, no. 3, pp. 390-402.</mixed-citation><mixed-citation xml:lang="en">Kebir H., Ifergan I., Alvarez J.I., Bernard M., Poirier J., Arbour N., Duquette P., Prat A. Preferential recruitment of interferon-gamma-expressing TH17 cells in multiple sclerosis. Ann. Neurol., 2009, Vol. 66, no. 3, pp. 390-402.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Kleinschek M.A., Boniface K., Sadekova S., Grein J., Murphy E.E., Turner S.P., Raskin L., Desai B., Faubion W.A., de Waal Malefyt R., Pierce R.H., McClanahan T., Kastelein R.A. Circulating and gut-resident human Th17 cells express CD161 and promote intestinal inflammation. J. Exp. Med., 2009, Vol. 206, no. 3, pp. 525-534.</mixed-citation><mixed-citation xml:lang="en">Kleinschek M.A., Boniface K., Sadekova S., Grein J., Murphy E.E., Turner S.P., Raskin L., Desai B., Faubion W.A., de Waal Malefyt R., Pierce R.H., McClanahan T., Kastelein R.A. Circulating and gut-resident human Th17 cells express CD161 and promote intestinal inflammation. J. Exp. Med., 2009, Vol. 206, no. 3, pp. 525-534.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Lee Y.K., Turner H., Maynard C.L., Oliver J.R., Chen D., Elson C.O., Weaver C.T. Late developmental plasticity in the T helper 17 lineage. Immunity, 2009, Vol. 30, no. 1, pp. 92-107.</mixed-citation><mixed-citation xml:lang="en">Lee Y.K., Turner H., Maynard C.L., Oliver J.R., Chen D., Elson C.O., Weaver C.T. Late developmental plasticity in the T helper 17 lineage. Immunity, 2009, Vol. 30, no. 1, pp. 92-107.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Littman D.R., Rudensky A.Y. Th17 and regulatory T cells in mediating and restraining inflammation. Cell, 2010, Vol. 140, no. 6, pp. 845-858.</mixed-citation><mixed-citation xml:lang="en">Littman D.R., Rudensky A.Y. Th17 and regulatory T cells in mediating and restraining inflammation. Cell, 2010, Vol. 140, no. 6, pp. 845-858.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Maggi L., Santarlasci V., Capone M., Rossi M.C., Querci V., Mazzoni A., Rolando Cimaz R., de Palma R., Liotta F., Maggi E., Romagnani S., Cosmi L., Annunziato F. Distinctive features of classic and nonclassic (Th17 derived) human Th1 cells. Eur. J. Immunol., 2012, Vol. 42, no. 12, pp. 3180-3188.</mixed-citation><mixed-citation xml:lang="en">Maggi L., Santarlasci V., Capone M., Rossi M.C., Querci V., Mazzoni A., Rolando Cimaz R., de Palma R., Liotta F., Maggi E., Romagnani S., Cosmi L., Annunziato F. Distinctive features of classic and nonclassic (Th17 derived) human Th1 cells. Eur. J. Immunol., 2012, Vol. 42, no. 12, pp. 3180-3188.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">McGeachy M.J., Chen Y., Tato C.M., Laurence A., Joyce-Shaikh B., Blumenschein W.M., McClanahan T.K., O’Shea J.J., Cua D.J. The interleukin 23 receptor is essential for the terminal differentiation of interleukin 17-producing effector T helper cells in vivo. Nat. Immunol., 2009, Vol. 10, no. 3, pp. 314-324.</mixed-citation><mixed-citation xml:lang="en">McGeachy M.J., Chen Y., Tato C.M., Laurence A., Joyce-Shaikh B., Blumenschein W.M., McClanahan T.K., O’Shea J.J., Cua D.J. The interleukin 23 receptor is essential for the terminal differentiation of interleukin 17-producing effector T helper cells in vivo. Nat. Immunol., 2009, Vol. 10, no. 3, pp. 314-324.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Nistala K., Adams S., Cambrook H., Ursu S., Olivito B., de Jager W., Evans J.G., Cimaz R., Bajaj-Elliott M., Wedderburn L.R. Th17 plasticity in human autoimmune arthritis is driven by the inflammatory environment. Proc. Natl Acad. Sci. USA, 2010, Vol. 107, no. 33, pp. 14751-14756</mixed-citation><mixed-citation xml:lang="en">Nistala K., Adams S., Cambrook H., Ursu S., Olivito B., de Jager W., Evans J.G., Cimaz R., Bajaj-Elliott M., Wedderburn L.R. Th17 plasticity in human autoimmune arthritis is driven by the inflammatory environment. Proc. Natl Acad. Sci. USA, 2010, Vol. 107, no. 33, pp. 14751-14756</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Quirant-Sanchez B., Presas-Rodriguez S., Mansilla M.J., Teniente-Serra A., Hervas-Garcia J.V., Brieva L., Moral-Torres E., Cano A., Munteis E., Navarro-Barriuso J., Martinez-Caceres E.M., Ramo-Tello C. Th1Th17CM lymphocyte subpopulation as a predictive biomarker of disease activity in multiple sclerosis patients under dimethyl fumarate or fingolimod treatment. Mediators Inflamm., 2019, Vol. 2019, pp. 8147803. doi: 10.1155/2019/8147803.</mixed-citation><mixed-citation xml:lang="en">Quirant-Sanchez B., Presas-Rodriguez S., Mansilla M.J., Teniente-Serra A., Hervas-Garcia J.V., Brieva L., Moral-Torres E., Cano A., Munteis E., Navarro-Barriuso J., Martinez-Caceres E.M., Ramo-Tello C. Th1Th17CM lymphocyte subpopulation as a predictive biomarker of disease activity in multiple sclerosis patients under dimethyl fumarate or fingolimod treatment. Mediators Inflamm., 2019, Vol. 2019, pp. 8147803. doi: 10.1155/2019/8147803.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Ramesh R., Kozhaya L., McKevitt K., Djuretic I.M., Carlson T.J., Quintero M.A., McCauley J.L., Abreu M.T., Unutmaz D., Sundrud M.S. Pro-inflammatory human Th17 cells selectively express P-glycoprotein and are refractory to glucocorticoids. J. Exp. Med., 2014, Vol. 211, no. 1, pp. 89-104.</mixed-citation><mixed-citation xml:lang="en">Ramesh R., Kozhaya L., McKevitt K., Djuretic I.M., Carlson T.J., Quintero M.A., McCauley J.L., Abreu M.T., Unutmaz D., Sundrud M.S. Pro-inflammatory human Th17 cells selectively express P-glycoprotein and are refractory to glucocorticoids. J. Exp. Med., 2014, Vol. 211, no. 1, pp. 89-104.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Ramstein J., Broos C.E., Simpson L.J., Ansel K.M., Sun S.A., Ho M.E., Woodruff P.G., Bhakta N.R., Christian L., Nguyen C.P., Antalek B.J., Benn B.S., Hendriks R.W., van den Blink B., Kool M., Koth L.L. IFN-γProducing T-Helper 17.1 Cells are increased in sarcoidosis and are more prevalent than T-Helper Type 1 Cells. Am. J. Respir. Crit. Care Med., 2016, Vol. 193, no. 11, pp.1281-1291.</mixed-citation><mixed-citation xml:lang="en">Ramstein J., Broos C.E., Simpson L.J., Ansel K.M., Sun S.A., Ho M.E., Woodruff P.G., Bhakta N.R., Christian L., Nguyen C.P., Antalek B.J., Benn B.S., Hendriks R.W., van den Blink B., Kool M., Koth L.L. IFN-γProducing T-Helper 17.1 Cells are increased in sarcoidosis and are more prevalent than T-Helper Type 1 Cells. Am. J. Respir. Crit. Care Med., 2016, Vol. 193, no. 11, pp.1281-1291.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
